Identification of anticancer drugs for hepatocellular carcinoma through personalized genome‐scale metabolic modeling

Genome‐scale metabolic models (GEMs) have proven useful as scaffolds for the integration of omics data for understanding the genotype–phenotype relationship in a mechanistic manner. Here, we evaluated the presence/absence of proteins encoded by 15,841 genes in 27 hepatocellular carcinoma (HCC) patients using immunohistochemistry. We used this information to reconstruct personalized GEMs for six HCC patients based on the proteomics data, HMR 2.0, and a task‐driven model reconstruction algorithm (tINIT). The personalized GEMs were employed to identify anticancer drugs using the concept of antimetabolites; i.e., drugs that are structural analogs to metabolites. The toxicity of each antimetabolite was predicted by assessing the in silico functionality of 83 healthy cell type‐specific GEMs, which were also reconstructed with the tINIT algorithm. We predicted 101 antimetabolites that could be effective in preventing tumor growth in all HCC patients, and 46 antimetabolites which were specific to individual patients. Twenty‐two of the 101 predicted antimetabolites have already been used in different cancer treatment strategies, while the remaining antimetabolites represent new potential drugs. Finally, one of the identified targets was validated experimentally, and it was confirmed to attenuate growth of the HepG2 cell line.

[1]  C. Lai,et al.  Quantitative morphology of mitochondria in hepatocellular carcinoma and chronic liver disease. , 1984, Archives of pathology & laboratory medicine.

[2]  C. Rebouche.  Quantitative estimation of absorption and degradation of a carnitine supplement by human adults. , 1991, Metabolism: clinical and experimental.

[3]  P. Lipsky,et al.  Regulation of proliferation and Ras localization in transformed cells by products of mevalonate metabolism. , 1997, Cancer research.

[4]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[5]  A human protein atlas for normal and disease tissue , 2005 .

[6]  A. Leong,et al.  Epidemiology and carcinogenesis of hepatocellular carcinoma. , 2005, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[7]  Erik K. Malm,et al.  A Human Protein Atlas for Normal and Cancer Tissues Based on Antibody Proteomics* , 2005, Molecular & Cellular Proteomics.

[8]  Y. Liu,et al.  Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer , 2006, Prostate Cancer and Prostatic Diseases.

[9]  G. Giannelli,et al.  Tyrosine kinase inhibitors: a potential approach to the treatment of hepatocellular carcinoma. , 2007, Current pharmaceutical design.

[10]  F. Pontén,et al.  Antibody-based tissue profiling as a tool for clinical proteomics , 2004, Clinical Proteomics.

[11]  Monica L. Mo,et al.  Global reconstruction of the human metabolic network based on genomic and bibliomic data , 2007, Proceedings of the National Academy of Sciences.

[12]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[13]  A. Walch,et al.  Inflammation and mitochondrial fatty acid β-oxidation link obesity to early tumor promotion , 2009, Proceedings of the National Academy of Sciences.

[14]  D. Kerr,et al.  Roles of tetrahydrobiopterin in promoting tumor angiogenesis. , 2010, The American journal of pathology.

[15]  R. Lencioni,et al.  The etiology of hepatocellular carcinoma and consequences for treatment. , 2010, The oncologist.

[16]  Maria Paola Costi,et al.  Novel approaches for targeting thymidylate synthase to overcome the resistance and toxicity of anticancer drugs. , 2010, Journal of medicinal chemistry.

[17]  J. Marrero,et al.  Recent advances in the treatment of hepatocellular carcinoma , 2010, Current opinion in gastroenterology.

[18]  K. Kaluarachchi,et al.  Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. , 2010, The Journal of clinical investigation.

[19]  G. Calais.  TPF: a rational choice for larynx preservation? , 2010, The oncologist.

[20]  R. Finn.  Development of Molecularly Targeted Therapies in Hepatocellular Carcinoma: Where Do We Go Now? , 2010, Clinical Cancer Research.

[21]  E. Lundberg,et al.  Towards a knowledge-based Human Protein Atlas , 2010, Nature Biotechnology.

[22]  B. Faubert,et al.  Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress. , 2011, Genes & development.

[23]  L. Hood,et al.  Predictive, personalized, preventive, participatory (P4) cancer medicine , 2011, Nature Reviews Clinical Oncology.

[24]  E. Ruppin,et al.  Predicting selective drug targets in cancer through metabolic networks , 2011, Molecular systems biology.

[25]  M. V. Heiden,et al.  Targeting cancer metabolism: a therapeutic window opens , 2011, Nature Reviews Drug Discovery.

[26]  Gabriela Kalna,et al.  Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase , 2011, Nature.

[27]  T. Librowski,et al.  L-carnitine--metabolic functions and meaning in humans life. , 2011, Current drug metabolism.

[28]  J. Bruix,et al.  Management of hepatocellular carcinoma: An update , 2011, Hepatology.

[29]  Min Wu,et al.  Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells. , 2011, Biochimica et biophysica acta.

[30]  Katsushi Inoue,et al.  Novel development of 5-aminolevurinic acid (ALA) in cancer diagnoses and therapy. , 2011, International immunopharmacology.

[31]  F. Rossi Fanelli,et al.  l-carnitine and cancer cachexia: Clinical and experimental aspects , 2011, Journal of cachexia, sarcopenia and muscle.

[32]  S. Lee,et al.  Integrative genome-scale metabolic analysis of Vibrio vulnificus for drug targeting and discovery , 2011, Molecular systems biology.

[33]  A. Lonardo,et al.  Potential for statins in the chemoprevention and management of hepatocellular carcinoma , 2012, Journal of gastroenterology and hepatology.

[34]  Mitchell A. Lazar,et al.  De-Meaning of Metabolism , 2012, Science.

[35]  Caroline Kampf,et al.  Production of Tissue Microarrays, Immunohistochemistry Staining and Digitalization Within the Human Protein Atlas , 2012, Journal of visualized experiments : JoVE.

[36]  A. Mardinoğlu,et al.  Systems medicine and metabolic modelling , 2012, Journal of internal medicine.

[37]  Anders Engeland,et al.  Metabolic risk factors and primary liver cancer in a prospective study of 578,700 adults , 2012, International journal of cancer.

[38]  Natapol Pornputtapong,et al.  Reconstruction of Genome-Scale Active Metabolic Networks for 69 Human Cell Types and 16 Cancer Types Using INIT , 2012, PLoS Comput. Biol..

[39]  Xin Lu,et al.  Analysis of urinary metabolic signatures of early hepatocellular carcinoma recurrence after surgical removal using gas chromatography-mass spectrometry. , 2012, Journal of proteome research.

[40]  J. Ricci,et al.  Cancer metabolism: current perspectives and future directions , 2012, Cell Death and Disease.

[41]  Hugo Y. K. Lam,et al.  Personal Omics Profiling Reveals Dynamic Molecular and Medical Phenotypes , 2012, Cell.

[42]  Rudi Balling,et al.  Revolutionizing medicine in the 21st century through systems approaches. , 2012, Biotechnology journal.

[43]  Jens Nielsen,et al.  Genome‐scale modeling of human metabolism – a systems biology approach , 2013, Biotechnology journal.

[44]  Y. Maehara,et al.  Autophagy enhances hepatocellular carcinoma progression by activation of mitochondrial β-oxidation , 2013, Journal of Gastroenterology.

[45]  Pier Paolo Pandolfi,et al.  Cancer metabolism: fatty acid oxidation in the limelight , 2013, Nature Reviews Cancer.

[46]  L. Montanaro,et al.  Carnitine-acyltransferase system inhibition, cancer cell death, and prevention of myc-induced lymphomagenesis. , 2013, Journal of the National Cancer Institute.

[47]  Intawat Nookaew,et al.  The RAVEN Toolbox and Its Use for Generating a Genome-scale Metabolic Model for Penicillium chrysogenum , 2013, PLoS Comput. Biol..

[48]  I. Nookaew,et al.  Integration of clinical data with a genome-scale metabolic model of the human adipocyte , 2013, Molecular systems biology.

[49]  Intawat Nookaew,et al.  Novel insights into obesity and diabetes through genome-scale metabolic modeling , 2013, Front. Physiol..

[50]  P. Valent,et al.  The impact of molecular targets in cancer drug development: major hurdles and future strategies , 2013, Expert review of clinical pharmacology.

[51]  Ronan M. T. Fleming,et al.  A community-driven global reconstruction of human metabolism , 2013, Nature Biotechnology.

[52]  M. Uhlén,et al.  Genome-scale metabolic modelling of hepatocytes reveals serine deficiency in patients with non-alcoholic fatty liver disease , 2014, Nature Communications.